Tarsus Pharmaceuticals Inc. (TARS)
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TARS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.60B
- Forward P/E
- 339.58
- EPS (TTM)
- -$15.86
- Dividend yield
- None
- 52-week range
- 53.89 – 91.53
- Day range
- 72.74 – 78.11
- Volume / Avg
- 706.77K / 871.07K
- Beta
- —
- Shares outstanding
- 49.31M
52-week range
TARS stock today
Tarsus Pharmaceuticals (TARS) closed at $73.01 on Nov 20, down 6.00% (-$4.66), versus the S&P 500's 3.70% decline. At this level, TARS sits in the middle of its 52-week range of $53.89 to $91.53: 20.2% below the high, set on Sep 4, 2026 and 35.5% above the low. TARS is down 10.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 8.3%.
Tarsus Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$15.86), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tarsus Pharmaceuticals
Company profileTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Bobak R. Azamian M.D.
- Headquarters
- Irvine, CA
- Employees
- 370
- IPO year
- 2020
- Website
- tarsusrx.com
Financial highlights
Full financialsIn fiscal 2025, Tarsus Pharmaceuticals generated $451.4 million in revenue, up 146.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Tarsus Pharmaceuticals reported a net loss of $66.4 million, compared with a loss of $115.6 million a year earlier. Operating margin was -15.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $451.36M | $182.95M | $17.45M | $25.82M | $57.03M |
| Growth | +146.71% | +948.62% | -32.42% | -54.73% | — |
| Net income | $-66.42M | $-115.55M | $-135.89M | $-62.09M | $-13.83M |
| EPS (diluted) | $-1.59 | $-3.07 | $-4.62 | $-2.52 | $-0.67 |
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$103.44+41.68%
- Strong buy 1
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-14.40 vs $-1.43
- Surprise
- -906.99%
TARS news
All TARS news- Tarsus to Participate in Upcoming Investor ConferencesGlobeNewswire
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthNasdaqHRMY, TGTX, TAK, TARS
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesNasdaqOCGN, TGTX, TARS
- Tarsus (TARS) Q3 2026 Earnings Call TranscriptNasdaq
- Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock UpNasdaqTEVA, BMY, TGTX, TARS
- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesNasdaqCORT, TGTX, TARS
- Tarsus Pharmaceuticals Q3 Net Loss Widens To $668 Mln On Acquisition Costs As XDEMVY Sales GrowNasdaqTARS, UHAL.B
- Tarsus Pharmaceuticals, Inc. Reports Record XDEMVY Net Product Sales of $194.6 million in Third Quarter 2026Nasdaq
Tarsus Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLAYRelay Therapeutics Inc. | 16.12 | +1.32% | $3.56B | vs TARS |
| CRSPCRISPR Therapeutics AG | 39.10 | +0.44% | $3.79B | vs TARS |
| IOVAIovance Biotherapeutics Inc. | 6.90 | -5.61% | $3.19B | vs TARS |
| DNLIDenali Therapeutics Inc. | 18.45 | +1.37% | $2.96B | vs TARS |
| VCELVericel Corporation | 57.52 | -1.27% | $2.94B | vs TARS |
| ADMAADMA Biologics Inc | 13.17 | -1.27% | $2.92B | vs TARS |
| ADPTAdaptive Biotechnologies Corporation | 27.93 | -0.43% | $4.52B | vs TARS |
| BEAMBeam Therapeutics Inc. | 20.90 | -0.19% | $2.16B | vs TARS |
Indexes, lists and sector
Tarsus Pharmaceuticals stock FAQ
What is Tarsus Pharmaceuticals's stock price today?
TARS last traded at $73.01 as of Nov 20, 4:00 PM EST, down 6.00% on the day. Prices are delayed at least 15 minutes.
Who is Tarsus Pharmaceuticals's CEO?
Dr. Bobak R. Azamian M.D. is the chief executive officer of Tarsus Pharmaceuticals Inc., which has about 370 employees.
What is the TARS 52-week high?
The 52-week high for TARS is $91.53 and the 52-week low is $53.89. The stock is currently 20.2% below its high.